Key result
Left atrial appendage occlusion demonstrates noninferiority to oral anticoagulants for stroke prevention in atrial fibrillation, with watchman FLX pericardial effusion rates declining to 0.51%.
Why the study?
Existing reviews on left atrial appendage occlusion needed an update integrating recent controversial trial data, device-specific outcomes, and contemporary techniques, imaging, and future directions.
Does left atrial appendage occlusion safely and effectively prevent stroke and systemic embolism compared to oral anticoagulation in patients with non-valvular atrial fibrillation?
Does left atrial appendage occlusion safely and effectively prevent stroke and systemic embolism compared to oral anticoagulation in patients with non-valvular atrial fibrillation?
This narrative review synthesizes contemporary surgical and transcatheter left atrial appendage occlusion techniques, imaging guidance, and clinical trial outcomes, highlighting improved procedural safety with newer generation devices alongside ongoing controversies in patient selection and peridevice leak management.
Answers are grounded in this paper and cite their sources.
Improved LAAO safety may inform decisions in anticoagulation-intolerant AF; leaves open comparative efficacy versus contemporary DOACs.
Left atrial appendage occlusion (LAAO) is an important strategy for stroke prevention in patients with non-valvular atrial fibrillation (AF) who have contraindications to long-term oral anticoagulation. We differentiate this review from existing literature by integrating recent controversial trial data and device-specific outcomes. Advances in technology and imaging have transformed LAAO into a widely adopted percutaneous therapy. Large trials and registries demonstrate LAAO’s non-inferiority to oral anticoagulants. For example, the PRAGUE-17 trial (N=402) found LAAO non-inferior to direct oral anticoagulants, while PROTECT-AF and PREVAIL 5-year data (N=1114) showed significant reductions in hemorrhagic stroke. The surgical LAAOS III trial (N=4811) demonstrated a 33% longterm reduction in stroke or systemic embolism. Major complications have declined; the SURPASS registry (N=16,446) demonstrated a 0.51% incidence of pericardial effusion for the WATCHMAN FLX. In the Amulet IDE trial, pericardial effusion occurred in 2.4% of Amulet patients versus 1.2% of WATCHMAN patients. Recent 2026 NEJM trials (CHAMPION-AF and CLOSURE-AF) reached opposite conclusions in different populations, remaining a central controversy. Emerging technologies like artificial intelligence-guided planning, which accurately predicted device size in 72.7% of cases, and low-thrombogenic devices continue to improve safety. This review summarizes contemporary techniques, imaging, complications, outcomes, and future directions.
No takes yet. Share an insight, caveat, or question.
Siddiqi et al. (2026) conducted a review in Non-valvular atrial fibrillation. Left atrial appendage occlusion (LAAO) vs. Oral anticoagulation (DOACs or warfarin) or no exclusion was evaluated on Stroke or systemic embolism and procedural complications (pericardial effusion, device embolization, peridevice leak). Left atrial appendage occlusion demonstrates noninferiority to oral anticoagulants for stroke prevention in atrial fibrillation, with watchman FLX pericardial effusion rates declining to 0.51%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: